erdrp-0519 erdrp-0519 erdrp-0519 is an antiviral drug which is the first drug specifically developed to target the measles morbillivirus. it acts as an inhibitor of the viral enzyme rna polymerase which is essential for viral replication, and in animal studies showed good oral bioavailability and protected ferrets from otherwise lethal doses of a morbillivirus when administered up to three days after infection. erdrp-0519legal statuslegal status us: investigational new drug identifiers iupac name 2-methyl-n-sulfonylphenyl]-5-(trifluoromethyl)pyrazole-3-carboxamide cas number1374006-96-8 ypubchem cid57521469chemspider28514843chemical and physical dataformulac23h30f3n5o4smolar mass529.574 g·mol−13d model (jsmol)interactive image smiles cn1c(cc(n1)c(f)(f)f)c(=o)nc2ccc(cc2)s(=o)(=o)n3cccc3ccn4ccocc4 inchi inchi=1s/c23h30f3n5o4s/c1-29-20(16-21(28-29)23(24,25)26)22(32)27-17-5-7-19(8-6-17)36(33,34)31-10-3-2-4-18(31)9-11-30-12-14-35-15-13-30/h5-8,16,18h,2-4,9-15h2,1h3,(h,27,32)/t18-/m0/s1key:jvzhtuqimbydsx-sfhvurjksa-n history the research was done at georgia state university and the paul ehrlich institute.